INTRODUCTION
Marrow transplantation is an effective treatment of severe aplastic anemia provided that an HLA identical sibling can be identified as the marrow donor. Between Received for publication 23 September 1976.
October 1970 and November 1975, 73 consecutive patients have been treated by marrow transplantation in Seattle and 31 (43%) are alive with complete hematologic restoration between 8 mo and 5 yr (1) (2) (3) (4) . The important role of marrow grafting in the treatment of severe aplastic anemia has been emphasized by a recent prospective trial which showed it to be more effective than conventional therapy (5) .
The still high mortality associated with marrow transplantation can largely be accounted for by two phenomena, both setting the stage for fatal infections: marrow graft rejection and graft versus host disease (GVHD).1 Marrow graft rejection has recently been the subject of a separate analysis (manuscript in preparation) and was found to be associated with two prognostic factors: positive in vitro tests of sensitization of marrow recipient against marrow donor (presumably reflecting transfusion induced immunity to minor transplantation antigens), and a low number of marrow cells used for transplantation (<3 x 108 cells/kg).
The present analysis was aimed at identifying prognostic factors associated with GVHD and survival in those patients who did not reject their marrow graft, but rather showed sustained marrow engraftment. For this purpose, proportional hazards and logistic regression models (6, 7) were applied to the data available from the patients pre and post transplantation courses. (Table IV) . Analysis offactors associated with GVHD. Table I and the more detailed summaries presented elsewhere (1) (2) (3) (4) show that GVHD was a major problem in patients with sustained engraftment. 28 Grade I GVHD is transient and the diagnosis cannot always be made definitively. For the current analysis, therefore, we combined GVHD grades 0 and I and compared them to grades II-IV by using the same factors as in the survival analysis above. Again, some suggested associations were found (Table V) . An increased incidence of GVHD (grades II-IV) was seen in patients who were sex or ABO mismatched with their donors and in patients who had been previously treated with androgens or were refractory to random donor platelets. Also, male patients seemed to have a higher incidence of GVHD. When these factors were entered into a binary logistic regression analysis (7) only sex mismatch showed a significant association with presence of grade II-IV GVHD (P < 0.01) though the exclusion ofsome other factors may simply reflect small numbers. Table VI shows the association of both sex match and GVHD grade to patient survival. The favorable influence of sex match on survival cannot be entirely explained in terms of absence of GVHD. Similarly, sex mismatch appears to have an unfavorable influence on survival that cannot be entirely explained by increased incidence of GVHD alone. DISCUSSION The results of the current study indicate that the occurrence of GVHD and survival of patients with aplastic anemia treated by marrow transplantation are strongly influenced by whether or not marrow donor and recipient are matched for sex. This strong association between sex match and survival (and absence of GVHD) remained highly significant (P < 0.01) Calculations of the chances of incompatibility for a hypothetical X-assocaited biallelic system suggest the following frequencies of incompatibilities (expressed as percent of the heterozygous frequlency): M F = 125%, \l M = 50%, F -* M = 25% and F F = 25%. Additional consideration of a Y-associated antigen system increases incompatibility in the F M combination to 100%.
Both X and Y associated transplantation antigens (H-Y, N-X) have been described in mice. The first observation on H-Y was made by Eichwald and Silmser in 1955 (13) . They found that intrastrain A/Jax mice skin grafts regularly failed when the donor was male and the recipient female. In contrast, M -> M, F -* F and F -* M grafts always succeeded. These ob- servations on skin engraftment were subsequently confirmed and extended by others (14) (15) (16) (17) (18) (19) (20) . In addition, Lengerova and Chutna in 1959 carried out marrow grafts after 900 R total body irradiation in C57B1 mice and found that survival of males given female grafts was inferior to that of all other combinations (21) . The causes of death of the mice in these studies, however, were not clearly described. One other group of investigators was unable to confirm these findings (22) . Parabiotic union of specifically sensitized C57 females with males of the same strain, however, resulted in parabiotic intoxication of50% ofthe latter (14) . Uphoff treated (C3Hf x NBL) F1 recipients with marrow grafts from both male and female reciprocal hybrid donors and reported 50% mortality from GVHD at 2 mo (23). She attributed GVHD to H-Y antigens. It was noted that the female response to H-Y varied depending on the strain used (15, 17, 18, 20, (24) (25) (26) ). An early response to H-Y was associated with H-2 haplotypes b and s, an intermediate response with haplotypes k, d, i, and h, and late or absent responses with H-2 haplotypes a and f. The H-2 linked gene determining male skin graft rejection is presumed to be either distally linked to or within the region containing K and Ir-l. Although the H-2 linked gene has a dominating influence on the response to H-Y, minor genetic factors or background effects probably contribute as well. This assumption is based on the finding of two different grades of immune responses to H-Y among six H-2b bearing mouse strains (20, (24) (25) (26) .
The first observation of histoincompatibility associated with the X chromosome in mice was made by Bailey in 1963 working with two highly inbred strains of mice (C57B1/6 JNBy and BALB/c AnNBy) and their reciprocal F, hybrids (27) . He not only observed that incompatibility for the X chromosome lead to skin graft rejection, but also found differences in survival of grafts from the reciprocal hybrids indicating that the antigenicity determined by the gene on the X chromosome of the one strain was stronger than that of the other strain. Bailey's findings were subsequently confirmed by other investigators (28) (29) (30) . It is interesting that Lengerova and Chutna (21) observed death of some C57B1 females given intrastrain male marrow grafts.
Overall, the X and Y associated transplantation antigens in mice appear to be weak as indicated by slow skin graft rejections. Similar weak male specific transplantation antigens have been reported in rats, rabbits, and platyfish (31) (32) (33) . In contrast, our observations suggest that X and Y associated transplantation antigens in man are rather strong and cause GVHD and increased mortality.
A second important prognostic factor in the present study was refractoriness to random donor platelets at the time of transplantation. 40% of our patients were refractory (2, 4) . Refractoriness was independent of the duration of aplastic anemia and the number of transfusions before transplantation and showed a significant association with mortality after transplantation (P < 0.05). Refractoriness adversely influenced only the survival ofthose patients who were sex mixmatched with their donors. It has to be remembered that refractoriness need not always reflect immunological refractoriness, the product of transfusion-induced sensitization to random platelets, but also can be the result of platelet consumption, e.g. in infection. Since 52% of our patients were infected at admission (2, 4) , the distinction between immunological and consumptive refractoriness was not always easy to make. Still, our observations are intriguing. We at first assumed that the influence of refractoriness on survival was due to differences in postgrafting transfusion support among the patients, i.e. differences in exposure to major and minor histocompatibility antigens on leukocytes and platelets in the transfused blood triggering varying degrees of immune responses of donor cells against host antigens. Statistical analysis of the data, however, (separately considering transfusions from the marrow donor, other family members and random donors) failed to show significant differences between the various groups of patients (refractory and nonrefractory, sex matched and mismatched). Another speculative explanation for the influence of refractoriness on survival involves the immune responsiveness of the marrow donor. As discussed earlier, immune responsiveness to the H-Y antigen in mice seems to be mainly associated with certain H-2 alleles although genetic background effects have also been observed. It has been speculated that early or late rejection of male skin by the female mouse may reflect general efficacy of the immune system rather than reactivity to a specific class of antigens. Refractoriness to random donor platelets could be the expression in man of strong general immune responsiveness as determined by Ir genes within the major histocompatibility complex. Since marrow donor and recipient were identical for the major histocompatibility complex, strong immune responsiveness seen in the recipient might also be present in the donor. In the case of a sex mismatch, strong immune responsiveness would be directed against X and Y-associated transplantation antigens resulting in a high incidence of GVHD and death. If this speculation were true and linkage disequilibrium between various loci of the major histocompatibility complex, is assumed, an association between refractoriness and certain HLA antigens might be expected. However, no significant deviation of HLA allele frequencies was seen among the small number of refractory patients nor among the patients with acute or chronic GVHD.
Our results differ from the results of an analysis carried out by the bone marrow transplant registry, (34) . They reported that the duration of aplastic anemia before transplantation, the number of pretransplant transfusions, and the age of the recipient correlated with survival. At least four factors may account for these differences: (a) the registry analyzed data from 17 transplant teams, data which are probably not derived from a consecutive series of patients and could be the result of selective reporting (patients from Seattle were not entered into the registry); (b) the registry did not differentiate between patients who rejected and patients with sustained engraftment. As discussed earlier, graft rejection in our series of patients was clearly associated with two different prognostic factors, a positive relative response index and low marrow cell dose. Mortality among patients with graft rejection was very high and never associated with GVHD while mortality among patients with sustained engraftment was lower and frequently associated with GVHD. Hence, it seems reasonable to analyze the two groups of patients separately; (c) the registry did not carry out multifactorial analyses which are more likely to isolate those factors that are really important for the success or failure of marrow transplantation; and (d) results of in vitro tests of sensitization, such as the relative response index, were not entered into the registry analysis. In view of the still small number of patients in our study, our results should be interpreted with caution. If true, they have some obvious therapeutic implications, e.g. selection of a sex matched marrow donor if several HLA identical siblings are available, and early transplantation (a) becuase of the excellent chances for survival in the case of a sex matched recipient, and (b) to prevent further deterioration of the chances for survival in the case of a sex mismatched recipient by avoiding the development of refractoriness. Knowledge of the association of antigens important for the development of GVHD with the X and Y chromosomes in man might lead to the development of in vitro typing techniques to detect these antigens. Availability of such typing techniques will facilitate the selection of donor recipient pairs for marrow transplantation in aplastic anemia.
